Newswise — Researchers studying mice made a serendipitous discovery that could lead to a new dry mouth treatment. More than 10% of people experience dry mouth, which can be caused by medical conditions, radiation treatment, certain medications and aging.

Abigail Boyd, a doctoral candidate at the University of South Alabama, and colleagues made the new discovery while exploring the anti-inflammatory benefits of inhibiting phosphodiesterase-4 (PDE4) enzymes in a mouse model of bacterial lung infection. After noticing that mice treated with a PDE4 inhibitor were salivating, they decided to examine whether this observation could be translated into a dry mouth therapy. They also looked at the implications of the discovery for cystic fibrosis, which causes persistent lung infections and limits the ability to breathe over time. 

“Saliva, while often taken for granted, is indispensable for oral health and overall well-being,” said Boyd. “New ways to treat dry mouth are needed since treatment options are currently limited.”

Boyd will present the new research at the American Society for Pharmacology and Experimental Therapeutics annual meeting during the virtual Experimental Biology (EB) 2021 meeting, to be held April 27–30. 

The researchers were working with several distinct PDE4 inhibitors including roflumilast, a PDE4 inhibitor that is used clinically for the treatment of chronic obstructive pulmonary disease. Their analysis revealed that PDE4 inhibitors increase salivation by inhibiting PDE4 in the salivary glands and in the autonomic nervous system, which regulates involuntary body processes such as breathing.

“Although the causes of salivary gland dysfunction are varied, there is often an inflammatory component,” said Boyd. “Thus, in addition to stimulating salivary secretions, PDE4 inhibition may also exert therapeutic benefits by alleviating the inflammatory responses that cause salivary gland dysfunction.” 

The researchers also studied the effects of PDE4 inhibition in a mouse model of cystic fibrosis. Cystic fibrosis occurs when the body doesn’t make the cystic fibrosis transmembrane conductance regulator (CFTR) protein or doesn’t make it correctly. This protein helps maintain the balance of salt and water on many surfaces in the body, including the lungs. In the new work, the researchers showed, for the first time that PDE4 controls CFTR-dependent salivation in mice. This finding suggests that PDE4 could have therapeutic potential for helping alleviate decreased CFTR function in patients with cystic fibrosis. 

The researchers are continuing to study the mechanisms at work in PDE4 inhibition and plan to find out if their findings translate to people.


Abigail Boyd will present the findings in poster R154 (abstract). Contact the media team for more information or to obtain a free press pass to access the meeting.


Image available.


About Experimental Biology 2021

Experimental Biology is an annual meeting comprised of thousands of scientists from five host societies and multiple guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the United States and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. #expbio


About the American Society for Pharmacology and Experimental Therapeutics (ASPET)

ASPET is a 4,000-member scientific society whose members conduct basic and clinical pharmacological research within the academic, industry and government sectors. Their members discover and develop new medicines and therapeutic agents that fight existing and emerging diseases, as well as increase our knowledge regarding how therapeutics affects humans.


Find more news briefs and tipsheets at:





Meeting Link: Experimental Biology 2021